Trial Profile

A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interleukin-7 (Primary)
Indications COVID 2019 infections; Hypoxaemia; Lymphopenia; Respiratory insufficiency
Focus Therapeutic Use
Acronyms ILIAD-7-US-I
Sponsors Revimmune SAS

30 Mar 2022 Status has been changed to discontinued.
15 Feb 2021 Planned End Date changed from 31 Mar 2021 to 31 Dec 2021.
15 Feb 2021 Planned primary completion date changed from 30 Dec 2020 to 30 Oct 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com